Author name: Sean Lightheart

The use of organoids for disease modelling, drug discovery and personalised medicine has become increasingly popular. Processes for the generation

New White Paper Released! The sourcing of primary tissue is vital for many fields of research and is becoming increasingly

Freshly obtained clinical tissue is used for several purposes including advanced diagnostic techniques, basic research and establishing physiologically relevant models for

We are proud to announce the beginning of a new distribution agreement with Scintila S.R.O, who will be distributing our

Atelerix has been awarded a place on the Global Business Innovation Programme for Biomanufacturing of Biologics and Advanced Therapies in

Atelerix Limited, which develops and markets innovative solutions for the storage and transport of cells, tissues, and viruses at hypothermic

Following on from LVPEI’s successful proof of concept studies highlighting the successful use of Atelerix’s technology to distribute a limbal-stromal cell therapy throughout

Another fantastic publication highlighting one of the multiple applications Atelerix products have within the scientific research and development industry. Anastassia

The liver microenvironment is proving to be a major obstacle to the success of immunotherapy in solid organ tumours. The

Branco et al. have recently published an excellent paper showing the benefits of Atelerix technology in the preservation of Adipose-Derived

How preservation of urine can impact kidney disease research Background: Each day, 20 people in the UK alone, develop chronic

Pancreatic cancer is one of the most aggressive and lethal solid tumours. Pancreatic ductal adenocarcinoma (PDAC) describes malignancies of the